[{"_1":2,"_67":-5,"_68":-5},"loaderData",{"_3":4,"_12":13},"root",{"_5":-5,"_6":7,"_8":9,"_10":11},"user","recaptchaSiteKey","6Ler9Q4rAAAAAIntb4jBhAbPRXMJSQVneAzxg5M8","sentryTrace","cf292b5ef25c31400cb05c634f8f1562-fd5610b89d0832eb-1","sentryBaggage","sentry-environment=production,sentry-public_key=fbef35ac88c344bffa6f98009cf3736c,sentry-trace_id=cf292b5ef25c31400cb05c634f8f1562,sentry-org_id=4505908219871232,sentry-transaction=GET%20http%3A%2F%2Fkargo.glos.si%2Fdomain%2Fcmigizr3v0036kw02141sb14o,sentry-sampled=true,sentry-sample_rand=0.09163228622195252,sentry-sample_rate=0.5","routes/domain.$domainId",{"_14":15,"_63":64,"_5":-5,"_65":66},"domain",{"_16":17,"_14":18,"_19":20,"_21":22,"_23":24,"_25":26,"_27":28,"_29":-5,"_30":-5,"_31":-5,"_32":33,"_43":44,"_49":50,"_61":62},"id","cmigizr3v0036kw02141sb14o","www.enhertuhcp.com","screenshotPath","sites/www.enhertuhcp.com/screenshot.jpg","htmlPath","sites/www.enhertuhcp.com/index.html","metaDescription","Discover ENHERTU, an FDA-approved treatment option. See Prescribing Information, including Boxed WARNINGS.","importantText","ENHERTU® (fam-trastuzumab deruxtecan-nxki) | Official HCP Site \n\n[Skip to content](#main-content)\n\nFor US Healthcare Professionals\n\n[![ENHERTU (fam-trastuzumab deruxtecan-nxki) Logo](/-/media/enhertu_landing_hcp/images/header/enhertu-logo-home.svg?rev=fb6db11f627a4ba8ab743cd66f074b40&la=en&h=57&w=221&hash=04C8AAF96CF6FB528AD2C7DFCFC07F1C)](/en/)\n\nFor US Healthcare Professionals\n\n* [Select an Indication](#)\n * [HER2+ mBC](/en/breast?utm_source=cross-site&utm_medium=hp_link)\n * [HER2-low and HER2-ultralow mBC](/en/her2-low-her2-ultralow-breast?utm_source=cross-site&utm_medium=hp_link)\n * [HER2+ (IHC 3+) Metastatic Solid Tumors](/en/ihc3-plus-metastatic-solid-tumors?utm_source=cross-site&utm_medium=hp_link)\n * [HER2+ aGC](/en/gastric?utm_source=cross-site&utm_medium=hp_link)\n * [_HER2_\\-mutant mNSCLC](/en/nsclc?utm_source=cross-site&utm_medium=hp_link)\n* [Important Safety Information](http://#isi_text)\n* [Prescribing Information](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true)\n* [Medication Guide](https://dsi.com/prescribing-information-portlet/getPIContent?productName=Enhertu_Med&inline=true)\n* [Patient Site](https://www.enhertu.com)\n\n* [Select an Indication](#)\n * [HER2+ mBC](/en/breast?utm_source=cross-site&utm_medium=hp_link)\n * [HER2-low and HER2-ultralow mBC](/en/her2-low-her2-ultralow-breast?utm_source=cross-site&utm_medium=hp_link)\n * [HER2+ (IHC 3+) Metastatic Solid Tumors](/en/ihc3-plus-metastatic-solid-tumors?utm_source=cross-site&utm_medium=hp_link)\n * [HER2+ aGC](/en/gastric?utm_source=cross-site&utm_medium=hp_link)\n * [_HER2_\\-mutant mNSCLC](/en/nsclc?utm_source=cross-site&utm_medium=hp_link)\n\n* [Home](/en/)\n* [Select an Indication](/en/breast?utm_source=cross-site&utm_medium=hp_link)\n * [HER2+ mBC](/en/breast?utm_source=cross-site&utm_medium=hp_link)\n * [HER2-low and HER2-ultralow mBC](/en/her2-low-her2-ultralow-breast?utm_source=cross-site&utm_medium=hp_link)\n * [HER2+ (IHC 3+) Metastatic Solid Tumors](/en/ihc3-plus-metastatic-solid-tumors?utm_source=cross-site&utm_medium=hp_link)\n * [HER2+ aGC](/en/gastric?utm_source=cross-site&utm_medium=hp_link)\n * [_HER2_\\-mutant mNSCLC](/en/nsclc?utm_source=cross-site&utm_medium=hp_link)\n* [MOA](/en/mechanism-of-action)\n* [Dosing](/en/dosing)\n * [Dosage](/en/dosing/dosage)\n * [Preparation and Administration](/en/dosing/preparation-and-administration)\n* [Managing Adverse Reactions](/en/managing-adverse-reactions)\n * [ILD/Pneumonitis](/en/managing-adverse-reactions/interstitial-lung-disease-pneumonitis)\n * [Neutropenia](/en/managing-adverse-reactions/neutropenia)\n * [Left Ventricular Dysfunction](/en/managing-adverse-reactions/lvef)\n * [Embryo-Fetal Toxicity](/en/managing-adverse-reactions/embryo-fetal-toxicity)\n * [Thrombocytopenia](/en/managing-adverse-reactions/thrombocytopenia)\n * [Other Select ARs](/en/managing-adverse-reactions/other-select-adverse-reactions)\n* [Support & Resources](/en/support-and-resources)\n * [For Healthcare Professionals](/en/support-and-resources/for-healthcare-professionals)\n * [For Patients and Caregivers](/en/support-and-resources/for-patients-and-caregivers)\n * [Request a Contact](/en/support-and-resources/request-a-contact)\n\n[](javascript:void\$0\$)\n\n* [Select an Indication](#)\n * [HER2+ mBC](/en/breast?utm_source=cross-site&utm_medium=hp_link)\n * [HER2-low and HER2-ultralow mBC](/en/her2-low-her2-ultralow-breast?utm_source=cross-site&utm_medium=hp_link)\n * [HER2+ (IHC 3+) Metastatic Solid Tumors](/en/ihc3-plus-metastatic-solid-tumors?utm_source=cross-site&utm_medium=hp_link)\n * [HER2+ aGC](/en/gastric?utm_source=cross-site&utm_medium=hp_link)\n * [_HER2_\\-mutant mNSCLC](/en/nsclc?utm_source=cross-site&utm_medium=hp_link)\n\n* [Home](/en/)\n* [MOA](/en/mechanism-of-action)\n* [Dosing](/en/dosing)\n * [Dosage](/en/dosing/dosage)\n * [Preparation and Administration](/en/dosing/preparation-and-administration)\n* [Managing Adverse Reactions](/en/managing-adverse-reactions)\n * [ILD/Pneumonitis](/en/managing-adverse-reactions/interstitial-lung-disease-pneumonitis)\n * [Neutropenia](/en/managing-adverse-reactions/neutropenia)\n * [Left Ventricular Dysfunction](/en/managing-adverse-reactions/lvef)\n * [Embryo-Fetal Toxicity](/en/managing-adverse-reactions/embryo-fetal-toxicity)\n * [Thrombocytopenia](/en/managing-adverse-reactions/thrombocytopenia)\n * [Other Select ARs](/en/managing-adverse-reactions/other-select-adverse-reactions)\n* [Support & Resources](/en/support-and-resources)\n * [For Healthcare Professionals](/en/support-and-resources/for-healthcare-professionals)\n * [For Patients and Caregivers](/en/support-and-resources/for-patients-and-caregivers)\n * [Request a Contact](/en/support-and-resources/request-a-contact)\n\n* [Important Safety Information](http://#isi_text)\n* [Prescribing Information](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true)\n* [Medication Guide](https://dsi.com/prescribing-information-portlet/getPIContent?productName=Enhertu_Med&inline=true)\n* [Patient Site](https://www.enhertu.com)\n\nFDA APPROVED IN \nMULTIPLE INDICATIONS1\n=======================================\n\nSelect Tumor Type:\n\n[\n\nHER2+ mBC \n(IHC 3+ or ISH+)\n\n![](/-/media/enhertu_landing_hcp/images/home/button.png?rev=ad84aed4d93f4dfb83d5d9cf3b5247ad&hash=BC8981543D07ECEAA96A06AC064C46FB)\n\n\n\n](/en/breast?utm_source=cross-site&utm_medium=hp_link)\n\n[\n\nHER2-low and \nHER2-ultralow mBC\n\n* Eligible HR+, HER2-low (IHC 1+ or IHC 2+/ISH–) or HER2-ultralow (IHC 0 with membrane staining) mBC\n* Eligible previously treated HER2-low (IHC 1+ or IHC 2+/ISH–) mBC\n\n![](/-/media/enhertu_landing_hcp/images/home/button.png?rev=ad84aed4d93f4dfb83d5d9cf3b5247ad&hash=BC8981543D07ECEAA96A06AC064C46FB)\n\n\n\n](/en/her2-low-her2-ultralow-breast?utm_source=cross-site&utm_medium=hp_link)\n\n[\n\nHER2+ Metastatic \nSolid Tumors \n(IHC 3+)\n\n![](/-/media/enhertu_landing_hcp/images/home/button.png?rev=ad84aed4d93f4dfb83d5d9cf3b5247ad&hash=BC8981543D07ECEAA96A06AC064C46FB)\n\n\n\n](/en/ihc3-plus-metastatic-solid-tumors?utm_source=cross-site&utm_medium=hp_link)\n\n[\n\nHER2+ aGC \n(IHC 3+ or IHC 2+/ISH+)\n\n![](/-/media/enhertu_landing_hcp/images/home/button.png?rev=ad84aed4d93f4dfb83d5d9cf3b5247ad&hash=BC8981543D07ECEAA96A06AC064C46FB)\n\n\n\n](/en/gastric?utm_source=cross-site&utm_medium=hp_link)\n\n[\n\n_HER2_\\-mutant \nmNSCLC\n\n![](/-/media/enhertu_landing_hcp/images/home/button.png?rev=ad84aed4d93f4dfb83d5d9cf3b5247ad&hash=BC8981543D07ECEAA96A06AC064C46FB)\n\n\n\n](/en/nsclc?utm_source=cross-site&utm_medium=hp_link)\n\nListed in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) across multiple metastatic solid tumors2-4,a\n\nNCCN Guidelines® lists fam-trastuzumab deruxtecan-nxki (ENHERTU) as a treatment option for multiple metastatic solid tumors.\n\n![LISTED IN NCCN GUIDELINES](/-/media/enhertu_landing_hcp/images/home/nccn-clinical-guidelines.png?rev=893102ef81bd4c5a9faba232919ea482&hash=8AFDAEC19972A53381A8E94FABB792A2)\n\nListed in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) across multiple metastatic solid tumors2-4,a \nNCCN Guidelines® lists fam-trastuzumab deruxtecan-nxki (ENHERTU) as a treatment option for multiple metastatic solid tumors.\n\naSee the NCCN Guidelines for detailed information.\n\naGC, advanced gastric cancer; FDA, Food and Drug Administration; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; ISH, in situ hybridization; mBC, metastatic breast cancer; mNSCLC, metastatic non-small cell lung cancer; NCCN, National Comprehensive Cancer Network® (NCCN®).\n\n[IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNINGS Expand](http://#isi)\n\nWARNING: INTERSTITIAL LUNG DISEASE and EMBRYO-FETAL TOXICITY\n\n* Interstitial lung disease (ILD) and pneumonitis, including fatal cases, have been reported with ENHERTU. Monitor for and promptly investigate signs and symptoms including cough, dyspnea, fever, and other new or worsening respiratory symptoms. Permanently discontinue ENHERTU in all patients with Grade 2 or higher ILD/pneumonitis. Advise patients of the risk and to immediately report symptoms.\n* Exposure to ENHERTU during pregnancy can cause embryo-fetal harm. Advise patients of these risks and the need for effective contraception.\n\nINDICATIONS\n\nENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with:\n\n* Unresectable or metastatic HER2-positive (IHC 3+ or ISH positive) breast cancer who have received a prior anti-HER2-based regimen either:\n * In the metastatic setting, or\n * In the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy\n* Unresectable or metastatic:\n * Hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by an FDA-approved test, that has progressed on one or more endocrine therapies in the metastatic setting\n * HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer, as determined by an FDA-approved test, who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy\n* Unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy\n \n This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.\n \n* Locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen\n* Unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options\n \n This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.\n \n\nContraindications\n\nNone.\n\nWarnings and Precautions\n\nInterstitial Lung Disease / Pneumonitis\n\nSevere, life-threatening, or fatal interstitial lung disease (ILD), including pneumonitis, can occur in patients treated with ENHERTU. A higher incidence of Grade 1 and 2 ILD/pneumonitis has been observed in patients with moderate renal impairment. Advise patients to immediately report cough, dyspnea, fever, and/or any new or worsening respiratory symptoms. Monitor patients for signs and symptoms of ILD. Promptly investigate evidence of ILD. Evaluate patients with suspected ILD by radiographic imaging. Consider consultation with a pulmonologist. For asymptomatic ILD/pneumonitis (Grade 1), interrupt ENHERTU until resolved to Grade 0, then if resolved in ≤28 days from date of onset, maintain dose. If resolved in >28 days from date of onset, reduce dose 1 level. Consider corticosteroid treatment as soon as ILD/pneumonitis is suspected (e.g., ≥0.5 mg/kg/day prednisolone or equivalent). For symptomatic ILD/pneumonitis (Grade 2 or greater), permanently discontinue ENHERTU. Promptly initiate systemic corticosteroid treatment as soon as ILD/pneumonitis is suspected (e.g., ≥1 mg/kg/day prednisolone or equivalent) and continue for at least 14 days followed by gradual taper for at least 4 weeks.\n\nHER2-Positive, HER2-Low, and HER2-Ultralow Metastatic Breast Cancer, HER2-Mutant NSCLC, and Solid Tumors (Including IHC 3+) (5.4 mg/kg)\n\nIn patients with metastatic breast cancer, HER2-mutant NSCLC, and other solid tumors treated with ENHERTU 5.4 mg/kg, ILD occurred in 12% of patients. Median time to first onset was 5.5 months (range: 0.9 to 31.5). Fatal outcomes due to ILD and/or pneumonitis occurred in 0.9% of patients treated with ENHERTU.\n\nHER2-Positive Locally Advanced or Metastatic Gastric Cancer (6.4 mg/kg)\n\nIn patients with locally advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma treated with ENHERTU 6.4 mg/kg, ILD occurred in 10% of patients. Median time to first onset was 2.8 months (range: 1.2 to 21).\n\nNeutropenia\n\nSevere neutropenia, including febrile neutropenia, can occur in patients treated with ENHERTU. Monitor complete blood counts prior to initiation of ENHERTU and prior to each dose, and as clinically indicated. For Grade 3 neutropenia (Absolute Neutrophil Count \\[ANC\\] <1.0 to 0.5 x 109/L), interrupt ENHERTU until resolved to Grade 2 or less, then maintain dose. For Grade 4 neutropenia (ANC <0.5 x 109/L), interrupt ENHERTU until resolved to Grade 2 or less, then reduce dose by 1 level. For febrile neutropenia (ANC <1.0 x 109/L and temperature >38.3º C or a sustained temperature of ≥38º C for more than 1 hour), interrupt ENHERTU until resolved, then reduce dose by 1 level.\n\nHER2-Positive, HER2-Low, and HER2-Ultralow Metastatic Breast Cancer, HER2-Mutant NSCLC, and Solid Tumors (Including IHC 3+) (5.4 mg/kg)\n\nIn patients with metastatic breast cancer, HER2-mutant NSCLC, and other solid tumors treated with ENHERTU 5.4 mg/kg, a decrease in neutrophil count was reported in 65% of patients. Nineteen percent had Grade 3 or 4 decreased neutrophil count. Median time to first onset of decreased neutrophil count was 22 days (range: 2 to 939). Febrile neutropenia was reported in 1.2% of patients.\n\nHER2-Positive Locally Advanced or Metastatic Gastric Cancer (6.4 mg/kg)\n\nIn patients with locally advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma treated with ENHERTU 6.4 mg/kg, a decrease in neutrophil count was reported in 72% of patients. Fifty-one percent had Grade 3 or 4 decreased neutrophil count. Median time to first onset of decreased neutrophil count was 16 days (range: 4 to 187). Febrile neutropenia was reported in 4.8% of patients.\n\nLeft Ventricular Dysfunction\n\nPatients treated with ENHERTU may be at increased risk of developing left ventricular dysfunction. Left ventricular ejection fraction (LVEF) decrease has been observed with anti-HER2 therapies, including ENHERTU. Assess LVEF prior to initiation of ENHERTU and at regular intervals during treatment as clinically indicated. Manage LVEF decrease through treatment interruption. When LVEF is >45% and absolute decrease from baseline is 10-20%, continue treatment with ENHERTU. When LVEF is 40-45% and absolute decrease from baseline is <10%, continue treatment with ENHERTU and repeat LVEF assessment within 3 weeks. When LVEF is 40-45% and absolute decrease from baseline is 10-20%, interrupt ENHERTU and repeat LVEF assessment within 3 weeks. If LVEF has not recovered to within 10% from baseline, permanently discontinue ENHERTU. If LVEF recovers to within 10% from baseline, resume treatment with ENHERTU at the same dose. When LVEF is <40% or absolute decrease from baseline is >20%, interrupt ENHERTU and repeat LVEF assessment within 3 weeks. If LVEF of <40% or absolute decrease from baseline of >20% is confirmed, permanently discontinue ENHERTU. Permanently discontinue ENHERTU in patients with symptomatic congestive heart failure. Treatment with ENHERTU has not been studied in patients with a history of clinically significant cardiac disease or LVEF <50% prior to initiation of treatment.\n\nHER2-Positive, HER2-Low, and HER2-Ultralow Metastatic Breast Cancer, HER2-Mutant NSCLC, and Solid Tumors (Including IHC 3+) (5.4 mg/kg)\n\nIn patients with metastatic breast cancer, HER2-mutant NSCLC, and other solid tumors treated with ENHERTU 5.4 mg/kg, LVEF decrease was reported in 4.6% of patients, of which 0.6% were Grade 3 or 4.\n\nHER2-Positive Locally Advanced or Metastatic Gastric Cancer (6.4 mg/kg)\n\nIn patients with locally advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma treated with ENHERTU 6.4 mg/kg, no clinical adverse events of heart failure were reported; however, on echocardiography, 8% were found to have asymptomatic Grade 2 decrease in LVEF.\n\nEmbryo-Fetal Toxicity\n\nENHERTU can cause fetal harm when administered to a pregnant woman. Advise patients of the potential risks to a fetus. Verify the pregnancy status of females of reproductive potential prior to the initiation of ENHERTU. Advise females of reproductive potential to use effective contraception during treatment and for 7 months after the last dose of ENHERTU. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ENHERTU and for 4 months after the last dose of ENHERTU.\n\nAdditional Dose Modifications\n\nThrombocytopenia\n\nFor Grade 3 thrombocytopenia (platelets <50 to 25 x 109/L) interrupt ENHERTU until resolved to Grade 1 or less, then maintain dose. For Grade 4 thrombocytopenia (platelets <25 x 109/L) interrupt ENHERTU until resolved to Grade 1 or less, then reduce dose by 1 level.\n\nAdverse Reactions\n\nHER2-Positive, HER2-Low, and HER2-Ultralow Metastatic Breast Cancer, HER2-Mutant NSCLC, and Solid Tumors (Including IHC 3+) (5.4 mg/kg)\n\nThe pooled safety population reflects exposure to ENHERTU 5.4 mg/kg intravenously every 3 weeks in 2233 patients in Study DS8201-A-J101 (NCT02564900), DESTINY-Breast01, DESTINY-Breast02, DESTINY-Breast03, DESTINY-Breast04, DESTINY-Breast06, DESTINY-Lung01, DESTINY-Lung02, DESTINY-CRC02, and DESTINY-PanTumor02. Among these patients, 67% were exposed for >6 months and 38% were exposed for >1 year. In this pooled safety population, the most common (≥20%) adverse reactions, including laboratory abnormalities, were decreased white blood cell count (73%), nausea (72%), decreased hemoglobin (67%), decreased neutrophil count (65%), decreased lymphocyte count (60%), fatigue (55%), decreased platelet count (48%), increased aspartate aminotransferase (46%), increased alanine aminotransferase (44%), increased blood alkaline phosphatase (39%), vomiting (38%), alopecia (37%), constipation (32%), decreased blood potassium (32%), decreased appetite (31%), diarrhea (30%), and musculoskeletal pain (24%).\n\nHER2-Positive Metastatic Breast Cancer\n\n_DESTINY-Breast03_\n\nThe safety of ENHERTU was evaluated in 257 patients with unresectable or metastatic HER2-positive breast cancer who received at least 1 dose of ENHERTU 5.4 mg/kg intravenously once every 3 weeks in DESTINY-Breast03. The median duration of treatment was 14 months (range: 0.7 to 30) for patients who received ENHERTU.\n\nSerious adverse reactions occurred in 19% of patients receiving ENHERTU. Serious adverse reactions in >1% of patients who received ENHERTU were vomiting, ILD, pneumonia, pyrexia, and urinary tract infection. Fatalities due to adverse reactions occurred in 0.8% of patients including COVID-19 and sudden death (1 patient each).\n\nENHERTU was permanently discontinued in 14% of patients, of which ILD/pneumonitis accounted for 8%. Dose interruptions due to adverse reactions occurred in 44% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose interruption were neutropenia, leukopenia, anemia, thrombocytopenia, pneumonia, nausea, fatigue, and ILD/pneumonitis. Dose reductions occurred in 21% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose reduction were nausea, neutropenia, and fatigue.\n\nThe most common (≥20%) adverse reactions, including laboratory abnormalities, were nausea (76%), decreased white blood cell count (74%), decreased neutrophil count (70%), increased aspartate aminotransferase (67%), decreased hemoglobin (64%), decreased lymphocyte count (55%), increased alanine aminotransferase (53%), decreased platelet count (52%), fatigue (49%), vomiting (49%), increased blood alkaline phosphatase (49%), alopecia (37%), decreased blood potassium (35%), constipation (34%), musculoskeletal pain (31%), diarrhea (29%), decreased appetite (29%), headache (22%), respiratory infection (22%), abdominal pain (21%), increased blood bilirubin (20%), and stomatitis (20%).\n\nHER2-Low and HER2-Ultralow Metastatic Breast Cancer\n\n_DESTINY-Breast06_\n\nThe safety of ENHERTU was evaluated in 434 patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer who received ENHERTU 5.4 mg/kg intravenously once every 3 weeks in DESTINY-Breast06. The median duration of treatment was 11 months (range: 0.4 to 39.6) for patients who received ENHERTU.\n\nSerious adverse reactions occurred in 20% of patients receiving ENHERTU. Serious adverse reactions in >1% of patients who received ENHERTU were ILD/pneumonitis, COVID-19, febrile neutropenia, and hypokalemia. Fatalities due to adverse reactions occurred in 2.8% of patients including ILD (0.7%); sepsis (0.5%); and COVID-19 pneumonia, bacterial meningoencephalitis, neutropenic sepsis, peritonitis, cerebrovascular accident, general physical health deterioration (0.2% each).\n\nENHERTU was permanently discontinued in 14% of patients. The most frequent adverse reaction (>2%) associated with permanent discontinuation was ILD/pneumonitis. Dose interruptions due to adverse reactions occurred in 48% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose interruption were COVID-19, decreased neutrophil count, anemia, pyrexia, pneumonia, decreased white blood cell count, and ILD. Dose reductions occurred in 25% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose reduction were nausea, fatigue, decreased platelet count, and decreased neutrophil count.\n\nThe most common (≥20%) adverse reactions, including laboratory abnormalities, were decreased white blood cell count (86%), decreased neutrophil count (75%), nausea (70%), decreased hemoglobin (69%), decreased lymphocyte count (66%), fatigue (53%), decreased platelet count (48%), alopecia (48%), increased alanine aminotransferase (44%), increased blood alkaline phosphatase (43%), increased aspartate aminotransferase (41%), decreased blood potassium (35%), diarrhea (34%), vomiting (34%), constipation (32%), decreased appetite (26%), COVID-19 (26%), and musculoskeletal pain (24%).\n\n_DESTINY-Breast04_\n\nThe safety of ENHERTU was evaluated in 371 patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who received ENHERTU 5.4 mg/kg intravenously once every 3 weeks in DESTINY-Breast04. The median duration of treatment was 8 months (range: 0.2 to 33) for patients who received ENHERTU.\n\nSerious adverse reactions occurred in 28% of patients receiving ENHERTU. Serious adverse reactions in >1% of patients who received ENHERTU were ILD/pneumonitis, pneumonia, dyspnea, musculoskeletal pain, sepsis, anemia, febrile neutropenia, hypercalcemia, nausea, pyrexia, and vomiting. Fatalities due to adverse reactions occurred in 4% of patients including ILD/pneumonitis (3 patients); sepsis (2 patients); and ischemic colitis, disseminated intravascular coagulation, dyspnea, febrile neutropenia, general physical health deterioration, pleural effusion, and respiratory failure (1 patient each).\n\nENHERTU was permanently discontinued in 16% of patients, of which ILD/pneumonitis accounted for 8%. Dose interruptions due to adverse reactions occurred in 39% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose interruption were neutropenia, fatigue, anemia, leukopenia, COVID-19, ILD/pneumonitis, increased transaminases, and hyperbilirubinemia. Dose reductions occurred in 23% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose reduction were fatigue, nausea, thrombocytopenia, and neutropenia.\n\nThe most common (≥20%) adverse reactions, including laboratory abnormalities, were nausea (76%), decreased white blood cell count (70%), decreased hemoglobin (64%), decreased neutrophil count (64%), decreased lymphocyte count (55%), fatigue (54%), decreased platelet count (44%), alopecia (40%), vomiting (40%), increased aspartate aminotransferase (38%), increased alanine aminotransferase (36%), constipation (34%), increased blood alkaline phosphatase (34%), decreased appetite (32%), musculoskeletal pain (32%), diarrhea (27%), and decreased blood potassium (25%).\n\nHER2-Mutant Unresectable or Metastatic NSCLC (5.4 mg/kg)\n\nDESTINY-Lung02 evaluated 2 dose levels (5.4 mg/kg \\[n=101\\] and 6.4 mg/kg \\[n=50\\]); however, only the results for the recommended dose of 5.4 mg/kg intravenously every 3 weeks are described below due to increased toxicity observed with the higher dose in patients with NSCLC, including ILD/pneumonitis.\n\nThe safety of ENHERTU was evaluated in 101 patients with HER2-mutant unresectable or metastatic NSCLC who received ENHERTU 5.4 mg/kg intravenously once every 3 weeks until disease progression or unacceptable toxicity in DESTINY-Lung02. Nineteen percent of patients were exposed for >6 months.\n\nSerious adverse reactions occurred in 30% of patients receiving ENHERTU. Serious adverse reactions in >1% of patients who received ENHERTU were ILD/pneumonitis, thrombocytopenia, dyspnea, nausea, pleural effusion, and increased troponin I. Fatality occurred in 1 patient with suspected ILD/pneumonitis (1%).\n\nENHERTU was permanently discontinued in 8% of patients. Adverse reactions which resulted in permanent discontinuation of ENHERTU were ILD/pneumonitis, diarrhea, decreased blood potassium, hypomagnesemia, myocarditis, and vomiting. Dose interruptions of ENHERTU due to adverse reactions occurred in 23% of patients. Adverse reactions which required dose interruption (>2%) included neutropenia and ILD/pneumonitis. Dose reductions due to an adverse reaction occurred in 11% of patients.\n\nThe most common (≥20%) adverse reactions, including laboratory abnormalities, were nausea (61%), decreased white blood cell count (60%), decreased hemoglobin (58%), decreased neutrophil count (52%), decreased lymphocyte count (43%), decreased platelet count (40%), decreased albumin (39%), increased aspartate aminotransferase (35%), increased alanine aminotransferase (34%), fatigue (32%), constipation (31%), decreased appetite (30%), vomiting (26%), increased alkaline phosphatase (22%), and alopecia (21%).\n\nHER2-Positive Locally Advanced or Metastatic Gastric Cancer (6.4 mg/kg)\n\nThe safety of ENHERTU was evaluated in 187 patients with locally advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma in DESTINY-Gastric01. Patients intravenously received at least 1 dose of either ENHERTU (N=125) 6.4 mg/kg every 3 weeks or either irinotecan (N=55) 150 mg/m2 biweekly or paclitaxel (N=7) 80 mg/m2 weekly for 3 weeks. The median duration of treatment was 4.6 months (range: 0.7 to 22.3) for patients who received ENHERTU.\n\nSerious adverse reactions occurred in 44% of patients receiving ENHERTU 6.4 mg/kg. Serious adverse reactions in >2% of patients who received ENHERTU were decreased appetite, ILD, anemia, dehydration, pneumonia, cholestatic jaundice, pyrexia, and tumor hemorrhage. Fatalities due to adverse reactions occurred in 2.4% of patients: disseminated intravascular coagulation, large intestine perforation, and pneumonia occurred in 1 patient each (0.8%).\n\nENHERTU was permanently discontinued in 15% of patients, of which ILD accounted for 6%. Dose interruptions due to adverse reactions occurred in 62% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose interruption were neutropenia, anemia, decreased appetite, leukopenia, fatigue, thrombocytopenia, ILD, pneumonia, lymphopenia, upper respiratory tract infection, diarrhea, and decreased blood potassium. Dose reductions occurred in 32% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose reduction were neutropenia, decreased appetite, fatigue, nausea, and febrile neutropenia.\n\nThe most common (≥20%) adverse reactions, including laboratory abnormalities, were decreased hemoglobin (75%), decreased white blood cell count (74%), decreased neutrophil count (72%), decreased lymphocyte count (70%), decreased platelet count (68%), nausea (63%), decreased appetite (60%), increased aspartate aminotransferase (58%), fatigue (55%), increased blood alkaline phosphatase (54%), increased alanine aminotransferase (47%), diarrhea (32%), decreased blood potassium (30%), vomiting (26%), constipation (24%), increased blood bilirubin (24%), pyrexia (24%), and alopecia (22%).\n\nHER2-Positive (IHC 3+) Unresectable or Metastatic Solid Tumors\n\nThe safety of ENHERTU was evaluated in 347 adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who received ENHERTU 5.4 mg/kg intravenously once every 3 weeks in DESTINY-Breast01, DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02. The median duration of treatment was 8.3 months (range 0.7 to 30.2).\n\nSerious adverse reactions occurred in 34% of patients receiving ENHERTU. Serious adverse reactions in >1% of patients who received ENHERTU were sepsis, pneumonia, vomiting, urinary tract infection, abdominal pain, nausea, pneumonitis, pleural effusion, hemorrhage, COVID-19, fatigue, acute kidney injury, anemia, cellulitis, and dyspnea. Fatalities due to adverse reactions occurred in 6.3% of patients including ILD/pneumonitis (2.3%), cardiac arrest (0.6%), COVID-19 (0.6%), and sepsis (0.6%). The following events occurred in 1 patient each (0.3%): acute kidney injury, cerebrovascular accident, general physical health deterioration, pneumonia, and hemorrhagic shock.\n\nENHERTU was permanently discontinued in 15% of patients, of which ILD/pneumonitis accounted for 10%. Dose interruptions due to adverse reactions occurred in 48% of patients. The most frequent adverse reactions (>2%) associated with dose interruption were decreased neutrophil count, anemia, COVID-19, fatigue, decreased white blood cell count, and ILD/pneumonitis. Dose reductions occurred in 27% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose reduction were fatigue, nausea, decreased neutrophil count, ILD/pneumonitis, and diarrhea.\n\nThe most common (≥20%) adverse reactions, including laboratory abnormalities, were decreased white blood cell count (75%), nausea (69%), decreased hemoglobin (67%), decreased neutrophil count (66%), fatigue (59%), decreased lymphocyte count (58%), decreased platelet count (51%), increased aspartate aminotransferase (45%), increased alanine aminotransferase (44%), increased blood alkaline phosphatase (36%), vomiting (35%), decreased appetite (34%), alopecia (34%), diarrhea (31%), decreased blood potassium (29%), constipation (28%), decreased sodium (22%), stomatitis (20%), and upper respiratory tract infection (20%).\n\nUse in Specific Populations\n\n* Pregnancy: ENHERTU can cause fetal harm when administered to a pregnant woman. Advise patients of the potential risks to a fetus. There are clinical considerations if ENHERTU is used in pregnant women, or if a patient becomes pregnant within 7 months after the last dose of ENHERTU.\n* Lactation: There are no data regarding the presence of ENHERTU in human milk, the effects on the breastfed child, or the effects on milk production. Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment with ENHERTU and for 7 months after the last dose.\n* Females and Males of Reproductive Potential: Pregnancy testing: Verify pregnancy status of females of reproductive potential prior to initiation of ENHERTU. Contraception: _Females_: ENHERTU can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment with ENHERTU and for 7 months after the last dose. _Males_: Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ENHERTU and for 4 months after the last dose. Infertility: ENHERTU may impair male reproductive function and fertility.\n* Pediatric Use: Safety and effectiveness of ENHERTU have not been established in pediatric patients.\n* Geriatric Use: Of the 1741 patients with HER2-positive, HER2-low, or HER2-ultralow breast cancer treated with ENHERTU 5.4 mg/kg, 24% were ≥65 years and 4.9% were ≥75 years. No overall differences in efficacy within clinical studies were observed between patients ≥65 years of age compared to younger patients. There was a higher incidence of Grade 3-4 adverse reactions observed in patients aged ≥65 years (61%) as compared to younger patients (52%). Of the 101 patients with HER2-mutant unresectable or metastatic NSCLC treated with ENHERTU 5.4 mg/kg, 40% were ≥65 years and 8% were ≥75 years. No overall differences in efficacy or safety were observed between patients ≥65 years of age compared to younger patients. Of the 125 patients with HER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma treated with ENHERTU 6.4 mg/kg in DESTINY-Gastric01, 56% were ≥65 years and 14% were ≥75 years. No overall differences in efficacy or safety were observed between patients ≥65 years of age compared to younger patients. Of the 192 patients with HER2-positive (IHC 3+) unresectable or metastatic solid tumors treated with ENHERTU 5.4 mg/kg in DESTINY-PanTumor02, DESTINY-Lung01, or DESTINY-CRC02, 39% were ≥65 years and 9% were ≥75 years. No overall differences in efficacy or safety were observed between patients ≥65 years of age compared to younger patients.\n* Renal Impairment: A higher incidence of Grade 1 and 2 ILD/pneumonitis has been observed in patients with moderate renal impairment. Monitor patients with moderate renal impairment more frequently. The recommended dosage of ENHERTU has not been established for patients with severe renal impairment (CLcr <30 mL/min).\n* Hepatic Impairment: In patients with moderate hepatic impairment, due to potentially increased exposure, closely monitor for increased toxicities related to the topoisomerase inhibitor, DXd. The recommended dosage of ENHERTU has not been established for patients with severe hepatic impairment (total bilirubin >3 times ULN and any AST).\n\nTo report SUSPECTED ADVERSE REACTIONS, contact Daiichi Sankyo, Inc. at 1-877-437-7763 or FDA at 1-800-FDA-1088 or [fda.gov/medwatch](https://www.fda.gov/medwatch).\n\nPlease [click here for full Prescribing Information](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true), including Boxed WARNINGS, and [click here for Medication Guide](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu_Med&inline=true).\n\nINDICATIONS\n\nENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with:\n\n* Unresectable or metastatic HER2-positive (IHC 3+ or ISH positive) breast cancer who have received a prior anti-HER2-based regimen either:\n * In the metastatic setting, or\n * In the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy\n* Unresectable or metastatic:\n * Hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by an FDA-approved test, that has progressed on one or more endocrine therapies in the metastatic setting\n * HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer, as determined by an FDA-approved test, who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy\n* Unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy\n \n This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.\n \n* Locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen\n* Unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options\n \n This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.\n \n\nReferences\n\n* ENHERTU. Prescribing information. Daiichi Sankyo, Inc.; 2025.\n* Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Cervical Cancer V.4.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed March 24, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.\n* Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Head and Neck Cancers V.2.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed January 17, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.\n* Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Uterine Neoplasms V.3.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed March, 7, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.\n\n* [Important Safety Information](#isi_text)\n* [Prescribing Information](https://dsi.com/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true)\n\n* [About Daiichi Sankyo](https://www.daiichisankyo.com/about_us/)\n* [Terms and Conditions](https://dsi.com/terms-and-conditions)\n* [Privacy Policy](https://dsi.com/privacy-notice)\n* [Contact Us](https://dsi.com/web/dsi/contact-us1)\n\n [![Go to Facebook](/-/media/enhertu_landing_hcp/images/footer/facebook-decorative-icon.png?rev=8e98b797cba94342b5579cd2c80a6d3a&la=en&h=32&w=33&hash=58712A915B4E4237D57EFB77DC3341DA)](https://www.facebook.com/ENHERTUHCP)[![Go to YouTube](/-/media/enhertu_landing_hcp/images/footer/youtube-decorative-icon.png?rev=c9c23245431b48bdbc3a30905a07c993&la=en&h=32&w=33&hash=A9BCCC9692A624F5919624BD4D219597) ](https://www.youtube.com/@ENHERTU)[![Go to LinkedIn](/-/media/enhertu_landing_hcp/images/footer/linkedin-decorative-icon.png?rev=c91557fede954698a06fafd72633658f&la=en&h=32&w=33&hash=A639A9D55AB7FF4065C6965F1246CC63) ](https://www.linkedin.com/company/enhertu-hcp/)[![Go to Reddit](/-/media/enhertu_landing_hcp/images/footer/reddit-decorative-icon.png?rev=234cf0bdab354593a871d0d3a22ef5f2&la=en&h=32&w=33&hash=029DAF24C722C32E256C911E0B4EFBA1)](https://www.reddit.com/user/ENHERTU_HCP/)\n\n* * *\n\n* * *\n\n![Go to Daiichi-Sankyo or AstraZeneca website](/Areas/EnhertuLanding_HCP/Content/images/daiichi-sankyo-astrazeneca-logo.png) \n\nTo contact us with questions or concerns about a Daiichi Sankyo product, please call us: 1-877-4DS-PROD ([1-877-437-7763](tel:1-877-437-7763))\n\nENHERTU® is a registered trademark of Daiichi Sankyo Company, Limited.\n\n© 2025 Daiichi Sankyo, Inc. and AstraZeneca. PP-US-EN-3004 07/25\n\nBack to top \n\n![](https://www.facebook.com/tr?id=3307323789503998&ev=PageView&noscript=1) ![](https://www.facebook.com/tr?id=5450640578330140&ev=PageView&noscript=1)\n\n**This Site Uses Cookies and Your Privacy Choice Is Important to Us.** Choose _Customize My Settings_ to make your privacy choices. Choose _Accept All Cookies_ to accept third-party cookies.[See our Privacy Policy](https://daiichisankyo.us/privacy-notice)\n\nCustomize My Settings Accept All Cookies\n\n![DSI Logo](https://cdn.cookielaw.org/logos/d81d7cfe-e2ef-457a-9e62-d8359d6168f6/018f3077-cdde-796c-9b46-e7522cc26d28/03e37416-b823-450e-99e2-ab843c297d83/Daiichi-Sankyo_Logo.png)\n\nPrivacy Preference Center\n-------------------------\n\n* ### Your Privacy\n \n* ### Strictly Necessary Cookies\n \n* ### Performance Cookies\n \n* ### Targeting Cookies\n \n\n#### Your Privacy\n\nWhen you visit our website, we store cookies on your browser to collect information. The information collected might relate to you, your preferences or your device, and is mostly used to make the site work as you expect it to and to provide a more personalized web experience. However, you can choose not to allow certain types of cookies, which may impact your experience of the site and the services we are able to offer. Click on the different category headings to find out more and change our default settings according to your preference. You cannot opt-out of our First Party Strictly Necessary Cookies as they are deployed in order to ensure the proper functioning of our website (such as prompting the cookie banner and remembering your settings, to log into your account, to redirect you when you log out, etc.). For more information about the First and Third Party Cookies used please follow this link. \n[More information](https://daiichisankyo.us/privacy-notice)\n\n#### Strictly Necessary Cookies\n\nAlways Active\n\nThese cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.\n\nCookies Details‎\n\n#### Performance Cookies\n\n Performance Cookies Active\n\nThese cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.\n\nCookies Details‎\n\n#### Targeting Cookies\n\n Targeting Cookies Active\n\nThese cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.\n\nCookies Details‎\n\nBack Button\n\n### Cookie List\n\nFilter Button\n\nConsent Leg.Interest\n\n checkbox label label\n\n checkbox label label\n\n checkbox label label\n\nClear\n\n checkbox label label\n\nApply Cancel\n\nConfirm My Choices\n\nAccept All Cookies\n\n[![Powered by Onetrust](https://cdn.cookielaw.org/logos/static/powered_by_logo.svg \"Powered by OneTrust Opens in a new Tab\")](https://www.onetrust.com/products/cookie-consent/)\n\nYour Privacy \\[\\`dialog closed\\`\\]\n\n![](https://t.co/1/i/adsct?bci=4&dv=UTC%2B0%26en-US%2Cen%26Google%20Inc.%26Linux%20x86_64%26255%26800%26600%264%2624%26800%26600%260%26na&eci=3&event=%7B%7D&event_id=9c75ac3f-9c2e-4e81-a854-4a259382bc23&integration=gtm&p_id=Twitter&p_user_id=0&pl_id=c037f644-0599-4b84-8364-213c8377b37f&pt=ENHERTU%C2%AE%20(fam-trastuzumab%20deruxtecan-nxki)%20%7C%20Official%20HCP%20Site&tw_document_href=https%3A%2F%2Fwww.enhertuhcp.com%2Fen&tw_iframe_status=0&txn_id=olyp7&type=javascript&version=2.3.35)![](https://analytics.twitter.com/1/i/adsct?bci=4&dv=UTC%2B0%26en-US%2Cen%26Google%20Inc.%26Linux%20x86_64%26255%26800%26600%264%2624%26800%26600%260%26na&eci=3&event=%7B%7D&event_id=9c75ac3f-9c2e-4e81-a854-4a259382bc23&integration=gtm&p_id=Twitter&p_user_id=0&pl_id=c037f644-0599-4b84-8364-213c8377b37f&pt=ENHERTU%C2%AE%20(fam-trastuzumab%20deruxtecan-nxki)%20%7C%20Official%20HCP%20Site&tw_document_href=https%3A%2F%2Fwww.enhertuhcp.com%2Fen&tw_iframe_status=0&txn_id=olyp7&type=javascript&version=2.3.35)\n\n![](https://thrtle.com/insync?vxii_pid=10015&vxii_pdid=)\n\n![](https://bh.contextweb.com/sr?action=add&token=L1HF9UJCLTXX&us_privacy=&gpp=${GPP_STRING_XXXXX}&gpp_sid=${GPP_SID}&ch=1&url=https%3A%2F%2Fwww.enhertuhcp.com%2Fen&rr=&campaign=none&frmtext=$$frmtext$$&clktext=$$clktext$$¶m1=$$param1$$¶m2=$$param2$$¶m3=$$param3$$¶m4=$$param4$$¶m5=$$param5$$&cpurl=https%3A%2F%2Fwww.enhertuhcp.com%2Fen&cprr=&cpid=8322&cpext=ch%3A1%7Ccampaign%3Anone%7Curl%3Ahttps%3A%3A%2F%2Fwww.enhertuhcp.com%2Fen%7Ctoken%3AL1HF9UJCLTXX)\n\n![](https://thrtle.com/insync?vxii_pid=10015&vxii_pdid=sQDu8BHOc7rP)\n\n![](https://bh.contextweb.com/sr?action=add&token=6PGPPEALLDXO&us_privacy=&ch=1&url=https%3A%2F%2Fwww.enhertuhcp.com%2Fen&rr=&campaign=none&frmtext=$$frmtext$$&clktext=$$clktext$$¶m1=$$param1$$¶m2=$$param2$$¶m3=$$param3$$¶m4=$$param4$$¶m5=$$param5$$&cpurl=https%3A%2F%2Fwww.enhertuhcp.com%2Fen&cprr=&cpid=7660&cpext=ch%3A1%7Ccampaign%3Anone%7Curl%3Ahttps%3A%3A%2F%2Fwww.enhertuhcp.com%2Fen%7Ctoken%3A6PGPPEALLDXO)","summary","The website serves as an official resource for healthcare professionals regarding the drug ENHERTU, providing information on indications, safety, prescribing, and patient resources.","notes","requests","dataTransferred","brands",[34],{"_16":35,"_36":37,"_38":39,"_40":41,"_42":-5},"cmhe8aizp00eel102kjmvav1a","name","ENHERTU","description","ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate used for treating various forms of HER2-positive cancers, including breast and gastric cancers, with specific indications based on prior treatment responses.","toCheck",true,"parentId","iabCategories",[45],{"_46":47,"_36":48,"_38":48},"code","IAB7","Health & Fitness","iabProducts",[51,58],{"_36":52,"_53":52,"_54":-5,"_55":-5,"_16":56,"_57":-5},"Health and Medical Services","tier1","tier2","tier3",1378,"parent_id",{"_36":59,"_53":59,"_54":-5,"_55":-5,"_16":60,"_57":-5},"Pharmaceuticals",1473,"tags",[],"creatives",[],"cdnUrl","https://d3a7qprliuujyh.cloudfront.net","actionData","errors"]

www.enhertuhcp.com

Summary

Associated Brands

IAB Categories

IAB Ad Products

Tags

Creatives